Search Within

Martin Henner Voss

  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (6)
  3. Research Letter (1)
Groups
  1. Department of Medicine (17)
  2. Gastrointestinal Oncology Service (17)
  3. Genitourinary Oncology Service (17)
  4. Solid Tumor Oncology Division (17)
  5. Thoracic Oncology (9)
  6. Hematologic Malignancies, Division of (8)

More Groups

People
  1. James Harding (13)
  2. Gopakumar Iyer (6)
  3. Alan Ho (4)
  4. Alexander Drilon (4)
  5. Ghassan Abou-Alfa (4)
  6. Jonathan Rosenberg (4)

More People

Years
  1. 2022 (2)
  2. 2021 (4)
  3. 2019 (3)
  4. 2018 (1)
  5. 2017 (3)
  6. 2016 (3)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Clinical Cancer Research (4)
  3. Cell (1)
  4. European Journal of Cancer (1)
  5. Genome Biology (1)
  6. Investigational New Drugs (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (4)
  3. American Medical Association (1)
  4. Biomed Central Ltd (1)
  5. Cell Press (1)
  6. Elsevier Inc. (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
    Meeting Abstract

    Meric-Bernstam, F.; Tannir, N. M.; Mier, J. W.; DeMichele, A.; Telli, M. L.; Fan, A. C.; Munster, P. N.; Carvajal, R. D.; Orford, K. W.; Bennett, M. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)
    Meeting Abstract

    Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures
    Journal Article

    Şenbabaoğlu, Y.; Gejman, R. S.; Winer, A. G.; Liu, M.; Van Allen, E. M.; de Velasco, G.; Miao, D.; Ostrovnaya, I.; Drill, E.; Luna, A.; more...
    Genome Biology (2016)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save